# Correction to “Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis”

PMC · DOI: 10.1002/jha2.934 · EJHaem · 2024-05-24

## Full-text entities

- **Diseases:** bone marrow fibrosis (MESH:D055728)
- **Chemicals:** ruxolitinib (MESH:C540383), momelotinib (MESH:C546012)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11182401/full.md

---
Source: https://tomesphere.com/paper/PMC11182401